Effective targeting of tumor vasculature by the angiogenesis inhibitors vasostatin and interleukin-12

Blood

Volumn 96, Issue 5, 2000, Pages 1900-1905

  Yao, L ^a   Pike, S E ^a   Setsuda, J ^a   Parekh, J ^a   Gupta, G ^a   Raffeld, M ^a   Jaffe, E S ^a   Tosato, G ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; INTERLEUKIN 12; UNCLASSIFIED DRUG; VASOSTATIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BURKITT LYMPHOMA; CANCER INHIBITION; COLON CARCINOMA; CONTROLLED STUDY; DRUG EFFICACY; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOMODULATION; MOUSE; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; TUMOR VASCULARIZATION;

EID: 0034284301     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v96.5.1900     Document Type: Article

References (49)

1. What is the evidence that tumors are angiogenesis dependent?
2. Tumor angiogenesis: Therapeutic implications
3. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
4. Vessel cooption, regression, and growth in tumors mediated by angiopoietins and VEGF
5. Isolation of putative progenitor endothelial cells for angiogenesis
6. Id1 and Id3 are required for neurogenesis, angiogenesis and vascularization of tumour xenografts
7. Angiogenesis
8. Mechanisms of endothelial growth control
9. Quantitative angiogenesis assays: Progress and problems
10. Angiogenesis inhibition in the context of endothelial cell biology
11. 1992 Mack Forster Award Lecture: Review, regulation of angiogenesis in vitro
12. Human dermal microvascular endothelial cells produce matrix metalloproteinases in response to angiogenic factors and migration
13. The chemokine receptor CCR4 in vascular recognition by cutaneous but not intestinal memory T cells
14. Determinants of tumor blood flow: A review
15. Differential expression of markers for endothelial cells, pericytes, and basal lamina in the microvascutature of tumors and granulation tissue
16. Tumor angiogenesis: Rapid induction of endothelial mitoses demonstrated by autoradiography
17. Regulation of the activity of a new inhibitor of angiogenesis by a cancer suppressor gene
18. Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1
19. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma
20. Macrophage-derived metalloelastase is responsible for the generation of angiostatin in Lewis lung carcinoma
21. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor
22. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo
23. Halting angiogenesis suppresses carcinoma cell invasion
24. Antisense targeting of basic fibroblast growth factor and fibroblast growth factor receptor-1 in human melanomas blocks intratumoral angiogenesis and tumor growth
25. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels
26. The role of alphav integrins during angiogenesis insights into potential mechanisms of action and clinical development
27. Calreticulin and calreticulin fragments are endothelial cell inhibitors that suppress tumor growth
28. Vasostatin, a calreticulin fragment, inhibits angiogenesis and suppresses tumor growth
29. Matrix metalloproteinases in angiogenesis: A moving target for therapeutic intervention
30. Angiostatin induces and sustains dormancy of human primary tumors in mice
31. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth
32. Antiangiogenic activity of the cleaved conformation of the serpin antithrombin
33. Contribution of natural killer cells to inhibition of angiogenesis by interleukin-12
34. Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10
35. Inhibition of angiogenesis in vivo by interteukin 12
36. Histological and immunophenotypic profile of nasal NK/T cell lymphomas from Peru: High prevalence of p53 overexpression
37. Relationships between intermediate TCR cells and NK1.1 + T cells in various immune organs: NK1.1 + T ceils are present within a population of intermediate TCR cells
38. Gene trees and hominoid phylogeny
39. A multiple comparison procedure for comparing several treatment with a control
40. Tumor cell responses to IFNgamma affect tumorigenicity and response to IL-12 therapy and antiangiogenesis
41. A role for deregulated c-Myc expression in apoptosis of Epstein-Barr virus-immortalized B cells
42. Cellular responses to interferon-gamma
43. Regression of experimental Burkitt's lymphoma induced by Epstein-Barr virus-immortalized human B cells
44. The CXC chemokines IP-10 and Mig are necessary for IL-12-mediated regression of the mouse RENCA tumor
45. Contribution of the CXC chemokines IP-10 and Mig to the antitumor effects of IL-12
46. Mig and IP-10: CXC chemokines that target lymphocytes
47. The IP-10 chemokine binds to a specific cell surface heparan sulfate site shared with platelet factor 4 and inhibits endothelial cell proliferation
48. The chemokine receptor CXCR3 mediates rapid and shear-resistant adhesion-induction of effector T lymphocytes by the chemokines IP10 and Mig
49. The CC chemokine 6Ckine binds the CXC chemokine receptor CXCR3